Lyme Disease Antibody w/ Reflex to Blot (IgG, IgM)

The Epstein-Barr Evaluation assesses several antibodies to the Epstein-Barr virus (EBV). It is performed to confirm active, past, or indeterminate infection for EBV-associated infectious mononucleosis.

The Lyme ImmunoBlot is a qualitative assay that detects antibodies to B. burgdorferi strains and species. This test includes IgG and IgM antibodies. IgM antibodies may be present as early as 1 week after a tick bite and will usually remain present for six to eight weeks after initial exposure. IgG antibodies are typically present a few months following initial infection. This test is unavailable for patients over 65 when ordered through physician services.

This test detects antibodies to the bacterium Borrelia burgdorferi. Lyme disease is caused by Borrelia burgdorferi and is transmitted to humans through the bite of infected black-legged ticks. Immunoblot testing will confirm a detected screening result.

This test measures IgG, IgA, and IgM antibodies to Candida albicans. Candida-specific antibodies can be significantly elevated in systemic candidiasis. These antibodies have been identified in healthy individuals while poor antibody response is observed in immunocompromised patients.

This is a single-marker test measuring IgG antibody response to EBV early antigen.